Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Inclusion Criteria: * Females may be enrolled if all 3 of the following criteria are met: * They are not pregnant; * They are not breastfeeding; and * They do not plan on becoming pregnant during the study; * Have underlying heterozygous familial hypercholesterolemia (HeFH) and/or a history of established ASCVD * Are on maximally tolerated lipid-modifying therapy as an adjunct to a lipid-lowering diet and other lifestyle modifications, defined as follows: * A statin at a maximally tolerated stable dose for at least 8 weeks prior to Screening * Atorvastatin 40 and 80 mg; and * Rosuvastatin 20 and 40 mg; * Ezetimibe with or without maximally tolerated statin for at least 8 weeks prior to Screening * Bempedoic acid with a maximally tolerated statin for at least 8 weeks prior to Screening * A PCSK-9 targeted therapy alone or in combination with other lipid-modifying therapy for at least 4 stable doses prior to Screening * Have a fasting serum LDL-C at Screening as follows: * Fasting serum LDL-C ≥ 55 to \< 100 mg/dL (≥1.4 to \<2.6 mmol/L) OR non-HDL-C ≥85 mg/dL (≥2.2 mmol/L) to \< 130 mg/dL (\<3.4 mmol/L) with at least 1 of the following risk enhancers at Screening; * Recent MI (\> 3 and \< 12 months prior to Randomization); * Type 2 diabetes mellitus; * Current daily cigarette smoking; * Age of \> 60 years; * High sensitivity C-reactive protein (hsCRP) ≥2.0 mg/L (≥19.0 nmol/L) at Screening or within 6 months prior to Screening * Fasting triglycerides (TG) \> 150 mg/dL (\>1.7 mmo…